Fri. Jun 25th, 2021

A transparent research method has been accomplished with the right tools and techniques to make this Dystonia Drug Market research report world-class. Two of the most widely used techniques namely SWOT analysis and Porter’s Five Forces Analysis have been used while generating this report. Competitive analysis conducted in this report puts light on the moves of the key players in the Healthcare industry such as new product launches, expansions, agreements, joint ventures, partnerships & recent acquisitions. Dystonia Drug Market research report adoption plays an essential role for the business growth as it supports with the better decision making, enhancing revenue generation, prioritizing market goals and results in profitable business.

Get Exclusive Sample Copy of This Report Here

Global dystonia drug market is expected to grow at a substantial CAGR in the forecast period of 2019-2026. The emergence of drugs used in the treatment of neurological and metabolic disorders, development of newer technologies and vulnerable dystonia disease patients are the key factors enhancing the market growth.

Few of the major competitors currently working in the dystonia drug market are Pfizer Inc, Novartis AG, Sanofi, Merck & Co, Aspen Holdings, China Shineway Pharmaceutical Group Limited, Boston Scientific Corporation, Ipsen Pharma, Revance Therapeutics, Inc, Merz Pharma, US WorldMeds, LLC, Medytox, Allergan, Taro Pharmaceutical Industries Ltd, Mentor Worldwide LLC, Eisai Co., Ltd and few among others.

Read Complete Details with TOC Here

Report Highlights:

  • Shifting Industry dynamics
  • In-depth Dystonia Drug Market segmentation
  • Historical, current and projected industry size Recent industry trends
  • Key Competition landscape
  • Strategies for key players and product offerings
  • Potential and niche segments/regions exhibiting promising growth
  • A neutral perspective towards market performance

Market Definition: Global Dystonia Drug Market

Dystonia is neurological movement disorder characterized by involuntary uncontrollable muscle contraction that results in slow repetitive movements or irregular postures. The irregular contraction causes muscles to twist involuntarily and affect different parts of the body. The person with dystonia may experience dragging leg, cramps in the foot, involuntary pulling of muscles of neck, uncontrollable blinking and difficulties in speech.

According to The Dystonia Society 2016, it was estimated over 70,000 patients were diagnosed dystonia in the United Kingdom. Growing number of incidence cases, accelerating demand of novel therapies and uses of drugs used in treatment of metabolic disorders are the key drivers for market growth.

Segmentation: Global Dystonia Drug Market

Dystonia Drug Market : By Therapy Type

  • Physical therapy
  • Speech therapy
  • Sensory manoeuvres

Dystonia Drug Market : By Treatment Type

  • Medication
  • Surgery

Dystonia Drug Market : By Mechanism of Class Type

  • Anticholinergic
  • Benzodiazepines
  • Dopaminergic Agents
  • Others

Dystonia Drug Market : By Route of administration

  • Oral
  • Injectable

Dystonia Drug Market : By End users

  • Hospitals
  • Homecare
  • Specialty Clinics
  • Others

Dystonia Drug Market : By Geography

  • North America
  • South America
  • Europe
  • Asia-Pacific
  • Middle East & Africa

Key Developments in the Dystonia Drug Market

  • In November 2017, Revance Therapeutics, Inc has received Orphan Drug designation from the US FDA for DaxibotulinumtoxinA for Injection (RT002) for the treatment of cervical dystonia. If approved, it will be the potential commercial milestone for Revance Therapeutics, Inc.
  • In March 2017, Ipsen Pharma received approval in Canada from the Health Canada for Dysport therapeutic (abobotulinumtoxina) for the treatment of cervical dystonia as well as for adult upper limb spasticity. This approval makes new treatment option available to patients with cervical dystonia in need throughout the Canada

Dystonia Drug Market Drivers

  • Increase in prevalence rate of dystonia disorders worldwide
  • Rising awareness about dystonia therapy and technological advancement is driving the growth of market
  • Increase in the rate of R&D initiatives is driving dystonia therapeutics market

Dystonia Drug Market Restraints

  • Effective treatment is either unavailable or unaffordable
  • Patent expiry from many companies and introduction of generic drugs of branded version is expected to restrain the growth if the market
  • Inadequate knowledge about dystonia in some developing countries

Want Full Report? Enquire Here

About Data Bridge Market Research:

Data Bridge Market Research is a versatile market research and consulting firm with over 500 analysts working in different industries. We have catered more than 40% of the fortune 500 companies globally and have a network of more than 5000+ clientele around the globe. Our coverage of industries include Medical Devices, Pharmaceuticals, Biotechnology, Semiconductors, Machinery, Information and Communication Technology, Automobiles and Automotive, Chemical and Material, Packaging, Food and Beverages, Cosmetics, Specialty Chemicals, Fast Moving Consumer Goods, Robotics, among many others.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude.We are content with our glorious 99.9 % client satisfying rate.

Contact Us

Data Bridge Market Research

US: +1 888 387 2818

UK: +44 208 089 1725

Hong Kong: +852 8192 7475
Mail: [email protected]